{"text": "If a success is observed in at least 6 patients , it will be possible to conclude that the response rate is above 25 % ( lower 90 % confidence interval for observed response rate 50 % ) .", "label": "", "metadata": {}, "score": "37.293194"}
{"text": "A negative score indicates improvement .At the end of the 10-minute math test , papers are collected and scored ; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to \" academic productivity . \"", "label": "", "metadata": {}, "score": "38.895138"}
{"text": "Scores from the 8 scales , PCS and MCS were transformed to the norm - based scores using weights from U.S. general population , with 50 as the average and 10 as the standard deviation , higher scores indicating better health .", "label": "", "metadata": {}, "score": "41.042297"}
{"text": "The ratings were based on both frequency and quality of specific behaviors .The rating scale is 0 ( normal , no impairment ) to 6 ( maximum impairment ) for a total possible combined score of 0 to 78 .", "label": "", "metadata": {}, "score": "44.97432"}
{"text": "Each item is rated on an 11-point numeric scale from 0 to 10 .Change From Baseline in Self - rating of Attractiveness [ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "45.25462"}
{"text": "Each item ranges from 1 to 7 .Therefore , the Brief Psychiatric Rating Scale total score ranges from a minimum of 0 to a maximum of 126 , where 126 indicates higher levels of behavioral symptoms .", "label": "", "metadata": {}, "score": "45.35013"}
{"text": "Total possible score is 0 - 24 .CGI - S was defined as 7-point clinician rated scale to assess severity of participant 's current illness state ; range : 1 ( normal - not ill at all ) to 7 ( among the most extremely ill participants ) .", "label": "", "metadata": {}, "score": "46.495026"}
{"text": "Percentage of Participants With a CR - SMFRS 2-grade Response [ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "47.48139"}
{"text": "MADRS measures the overall severity of depressive symptoms .The MADRS had a 10-item checklist .Items are rated on a scale of 0 - 6 , for a total numeric range of scores from 0 ( depressive symptoms absent ) to 60 ( numerically highest level of depressive symptoms ) .", "label": "", "metadata": {}, "score": "47.606995"}
{"text": "MADRS measures the overall severity of depressive symptoms .The MADRS had a 10-item checklist .Items are rated on a scale of 0 - 6 , for a total numeric range of scores from 0 ( depressive symptoms absent ) to 60 ( numerically highest level of depressive symptoms ) .", "label": "", "metadata": {}, "score": "47.606995"}
{"text": "At the end of the 10-minute math test , papers are collected and scored ; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to \" academic productivity . \"", "label": "", "metadata": {}, "score": "47.669678"}
{"text": "Items are rated on a scale of 0 - 10 visual analog scale , for a total numeric range of scores from 0 ( not at all impaired ) to 30 ( extremely impaired ) .", "label": "", "metadata": {}, "score": "48.366707"}
{"text": "CGI - I was defined as a 7-point clinician rated scale ranging from 1 ( very much improved ) to 7 ( very much worse ) .", "label": "", "metadata": {}, "score": "50.517754"}
{"text": "Although not formally rated , this improvement is equivalent to a Clinical Global Impression of Change ( CGIC ) rating of no more than minimal improvement ( improvement is noticed by not enough to improve patient function or caregiver 's practical management of the patient ) .", "label": "", "metadata": {}, "score": "50.60443"}
{"text": "The rating scale is 0 ( normal , no impairment ) to 6 ( maximum impairment ) for a total possible combined score of 0 to 36 for the Deportment subscale .", "label": "", "metadata": {}, "score": "50.608246"}
{"text": "Total Score at Weeks 11 and 14 [ Time Frame : Weeks 8 ( double - blind baseline ) , 11 and 14 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "50.610374"}
{"text": "Change From Baseline in CR - SMFRS Score [ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "52.267105"}
{"text": "Higher scores correspond to more severe symptom or disease .Change From Baseline in the Dermatology Life Quality Index ( DLQI ) Total Score at Week 16 [ Time Frame : Baseline to Week 16 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.89753"}
{"text": "A favourable clinical response was defined a priori as a decrease of more than 50 % from baseline in Young Mania Rating Scale total score .", "label": "", "metadata": {}, "score": "54.078995"}
{"text": "PASI-75 response is the percentage of participants who achieved at least a 75 % reduction ( improvement ) from baseline in PASI score at Week 16 .", "label": "", "metadata": {}, "score": "54.310585"}
{"text": "Percentage of Participants With a Subject Self Rating Scale ( SSRS ) Response [ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "54.52352"}
{"text": "Change From Baseline in the Mental Component Summary ( MSC ) Score of the Medical Outcome Study Short Form 36-item ( SF-36 )Health Survey Version 2.0 at Week 16 [ Time Frame : Baseline to Week 16 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "55.100826"}
{"text": "Percentage of Participants With a Clinician - Reported Submental Fat Rating Scale ( CR - SMFRS ) 1-grade Response [ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "55.187088"}
{"text": "Improvement in the treatment burden defined as the possibility to decrease the dose or stop some of the drugs used at entry [ Time Frame : at day 21 and month 12 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "55.401756"}
{"text": "Using the intent - to - treat analysis , the VPA group showed a significant fall in YMRS total scores after week 1 while the CBZ group showed a significant fall after week 2 .", "label": "", "metadata": {}, "score": "56.000256"}
{"text": "The improvement in PASI score was used as a measure of efficacy .See Outcome Measure # 1 for further description .See OCM # 2 for further description .", "label": "", "metadata": {}, "score": "57.047523"}
{"text": "Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 ( no involvement ) to 6 ( 90 % to 100 % involvement ) .", "label": "", "metadata": {}, "score": "57.36719"}
{"text": "The rating scale is 0 ( normal , no impairment ) to 6 ( maximum impairment ) for a total possible combined score of 0 to 42 for the Attention subscale .", "label": "", "metadata": {}, "score": "57.8134"}
{"text": "Secondary criteria include Kendall 's muscular testing or MG muscular score at day 21 and month 7 , quality of life auto - questionnaire ( SF 36 ) , evolution of CK levels and AAb titers .", "label": "", "metadata": {}, "score": "57.870045"}
{"text": "A negative score indicates improvement .SKAMP is a 13-item rating scale consisting of 2 subscales ( 7-items for Attention and 6-items for Deportment ) that measures classroom manifestations of ADHD .", "label": "", "metadata": {}, "score": "58.49527"}
{"text": "A negative score indicates improvement .Original Primary Outcome Measures ICMJE ( submitted : October 16 , 2008 ) .To evaluate the change in the Swanson , Kotkin , Agler , M Flynn and Pelham ( SKAMP ) combined , Attention and Deportment scores at 10 , 11 and 12 hour time points ( post - dose ) .", "label": "", "metadata": {}, "score": "61.325905"}
{"text": "Each Neuropsychiatric Inventory item ranges from 0 to 12 .Therefore the Neuropsychiatric Inventory total score has a minimum total value of 0 and maximum 144 , where 144 indicates higher levels of behavioral symptoms .", "label": "", "metadata": {}, "score": "62.90747"}
{"text": "PASI score is based on an assessment of erythema ( reddening ) , induration ( plaque thickness ) , desquamation ( scaling ) , and the percent area affected as observed on the day of examination .", "label": "", "metadata": {}, "score": "63.009766"}
{"text": "Score at Week 16 [ Time Frame : Baseline to Week 16 ] [ Designated as safety issue : No ] .Psoriasis Area Severity Index ( PASI ) scores range from 0 to 72 , with higher scores reflecting greater disease severity .", "label": "", "metadata": {}, "score": "63.049744"}
{"text": "Current Secondary Outcome Measures ICMJE ( submitted : February 22 , 2011 ) .SKAMP is a 13-item rating scale consisting of 2 subscales ( 7-items for Attention and 6-items for Deportment ) that measures classroom manifestations of ADHD .", "label": "", "metadata": {}, "score": "63.34021"}
{"text": "Two patients ( 4.8 % ) suffered SICH and there were 3 ( 7.1 % ) deaths .CONCLUSION :Thrombolysis in routine clinical practice in a South African setting has similar safety and early efficacy outcomes to controlled trials and open - label studies in developing and developed countries .", "label": "", "metadata": {}, "score": "63.812023"}
{"text": "Two patients ( 4.8 % ) suffered SICH and there were 3 ( 7.1 % ) deaths .CONCLUSION :Thrombolysis in routine clinical practice in a South African setting has similar safety and early efficacy outcomes to controlled trials and open - label studies in developing and developed countries .", "label": "", "metadata": {}, "score": "63.812023"}
{"text": "Two patients ( 4.8 % ) suffered SICH and there were 3 ( 7.1 % ) deaths .CONCLUSION :Thrombolysis in routine clinical practice in a South African setting has similar safety and early efficacy outcomes to controlled trials and open - label studies in developing and developed countries .", "label": "", "metadata": {}, "score": "63.812023"}
{"text": "Inadequate response is defined as the lack of improvement and/or the degradation of evaluation parameters ( defined bellow ) despite these conventional therapies , that led to a modification or a reintroduction of treatment .", "label": "", "metadata": {}, "score": "64.47905"}
{"text": "Inadequate response is defined as the lack of improvement and/or the degradation of evaluation parameters ( defined bellow ) despite these conventional therapies , that led to a modification or a reintroduction of treatment .", "label": "", "metadata": {}, "score": "64.47905"}
{"text": "Change From Baseline in Patient - reported Submental Fat Rating Scale ( PR - SMFRS )[ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.57443"}
{"text": "Change From Double - blind Baseline in Sheehan Disability Scale ( SDS ) Subscale Score at Weeks 11 and 14 [ Time Frame : Weeks 8 ( double - blind baseline ) , 11 and 14 ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "65.37523"}
{"text": "These values for each anatomic region are summed to yield the PASI score .The PASI score was set to missing if any severity score or degree of involvement is missing .", "label": "", "metadata": {}, "score": "65.4151"}
{"text": "Medically able to undergo the administration of study material determined by clinical evaluations made within 56 days before and laboratory tests obtained within 28 days before randomization for which the investigator identified no clinically significant abnormality .", "label": "", "metadata": {}, "score": "65.633316"}
{"text": "Treatment with an investigational device or agent within 30 days of randomization .Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "65.75342"}
{"text": "Change in Brief Psychiatric Rating Scale ( BPRS ) Total Score Over the Course of Study Participation [ Time Frame : Weeks 2 , 4 , 6 , and 8 ( change from Baseline ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.481476"}
{"text": "The instrument contains ten items dealing with the participant 's skin .With the exception of Item Number 7 , the participant responds on a four - point scale , ranging from \" Very Much \" ( score 3 ) to \" Not at All \" or \" Not relevant \" ( score 0 ) .", "label": "", "metadata": {}, "score": "66.67854"}
{"text": "It may be a new intercurrent illness , a worsening concomitant illness , an injury , or any concomitant impairment of the participant 's health , including laboratory test values regardless of etiology .", "label": "", "metadata": {}, "score": "66.890274"}
{"text": "A Randomized Phase 2a , Double - Blind , Placebo - Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression .", "label": "", "metadata": {}, "score": "66.96387"}
{"text": "Subjects meeting the DSM - IV criteria for primary diagnosis of ADHD - Combined type , or predominantly hyperactive - impulsive subtype , as established by the K - SADS - PL ( Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version ) .", "label": "", "metadata": {}, "score": "67.33477"}
{"text": "This study was able to test for efficacy ( improvement of signs and symptoms ) and safety of apremilast in patients with moderate to severe psoriasis .", "label": "", "metadata": {}, "score": "67.37434"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : October 16 , 2008 ) .To evaluate the change in the Swanson , Kotkin , Agler , M Flynn and Pelham ( SKAMP ) combined , Attention and Deportment scores at 3 , 6 , 9 , 10 , 11 and 12 hour time points ( post - dose ) .", "label": "", "metadata": {}, "score": "68.158875"}
{"text": "To evaluate the efficacy of Dex - Methylphenidate as measured by the Product Measure of Performance ( math test ) at hours 3 , 6 , 9 , 10 , 11 and 12 post - dose .", "label": "", "metadata": {}, "score": "68.22543"}
{"text": "Dissatisfaction with the submental area rated by the subject as 0 , 1 , 2 , or 3 using the Subject Self Rating Scale ( SSRS ) .", "label": "", "metadata": {}, "score": "68.45189"}
{"text": "The primary safety measures were the rates of symptomatic intracranial haemorrhage ( SICH ) and death .RESULTS : From January 2000 to February 2011 42 patients were thrombolysed , with a mean time to tPA infusion of 160 minutes ( standard deviation ( SD ) 50 ; range 60 - 270 ) .", "label": "", "metadata": {}, "score": "68.84439"}
{"text": "The primary safety measures were the rates of symptomatic intracranial haemorrhage ( SICH ) and death .RESULTS : From January 2000 to February 2011 42 patients were thrombolysed , with a mean time to tPA infusion of 160 minutes ( standard deviation ( SD ) 50 ; range 60 - 270 ) .", "label": "", "metadata": {}, "score": "68.84439"}
{"text": "The primary safety measures were the rates of symptomatic intracranial haemorrhage ( SICH ) and death .RESULTS : From January 2000 to February 2011 42 patients were thrombolysed , with a mean time to tPA infusion of 160 minutes ( standard deviation ( SD ) 50 ; range 60 - 270 ) .", "label": "", "metadata": {}, "score": "68.84439"}
{"text": "The Sheehan Suicidality Tracking Scale ( STS ) measures treatment - emergent suicidal ideation as well as behaviors .It can be administered by a clinician or filled in by a participant .", "label": "", "metadata": {}, "score": "69.31018"}
{"text": "Change From Baseline in Patient - Reported Submental Fat Impact Scale ( PR - SMFIS )[ Time Frame : Baseline and 12 weeks after last treatment ( up to 24 weeks after first dose ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.00878"}
{"text": "Relationship of demographic variables ( gender , age , body weight , height and ethnicity ) , concomitant medications and measures of altered hepatic and renal function were examined by fitting measured CP-601,927 concentrations .", "label": "", "metadata": {}, "score": "70.23289"}
{"text": "The HAM - D25 is the 25-item version of a scale used to assess the range of depressive symptoms including depressed mood , work and activities , sleep , suicidal thinking , psychomotor agitation / retardation , appetite , sexual interest , anxiety , somatic symptoms , and cognitive symptoms .", "label": "", "metadata": {}, "score": "70.53551"}
{"text": "The study was stopped at interim analysis in August 2011 , as stopping criteria for futility were met .There was no statistically significant change on the primary efficacy scale in favor of the drug .", "label": "", "metadata": {}, "score": "70.72454"}
{"text": "Corticosteroids and other immunosuppressive therapies presented also many side effects .Twenty fourth patients with primary IM ( 12 with anti - synthetase , 12 with anti - SRP AAbs ) , and 12 with MG will be included in the study .", "label": "", "metadata": {}, "score": "70.72858"}
{"text": "Subjects who are currently taking antidepressants or other psychotropic medication .Subjects who have initiated psychotherapy during the three months prior to randomization .Subjects with a positive urine drug screen .", "label": "", "metadata": {}, "score": "70.885414"}
{"text": "The Css of VPA ranged from 50 to 100 \u00b5g / ml ; a linear correlation was found between the dose and serum levels of VPA as well as between weekly rise in serum levels and clinical response .", "label": "", "metadata": {}, "score": "71.11287"}
{"text": "The degree to which irritability interferes with work , social and family function is also queried .The total SIS score is the sum of 7 items .", "label": "", "metadata": {}, "score": "71.34561"}
{"text": "The SIS also records the number of days impaired by irritability .Change From Double - blind Baseline in Sheehan Disability Scale ( SDS ) Total Score at Weeks 11 and 14 [ Time Frame : Weeks 8 ( double - blind baseline ) , 11 and 14 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "71.709114"}
{"text": "Erythema , thickness , and scaling are scored on a scale of 0 ( none ) to 4 ( very severe ) on 4 anatomic regions of the body : head , trunk , upper limbs , and lower limbs .", "label": "", "metadata": {}, "score": "71.9088"}
{"text": "Subjects initially randomized to apremilast 30 mg twice a day , and who demonstrate a PASI 75 response at Week 32 will be randomized ( 1 to 1 ) to either continue to receive apremilast 30 mg ) BID or to receive placebo ( until effect is lost ) .", "label": "", "metadata": {}, "score": "72.54233"}
{"text": "The PASI score was set to missing if any severity score or degree of involvement is missing .In the event of different severities across disease signs , the sign that is the predominant feature of the disease should be used to help determine the sPGA score .", "label": "", "metadata": {}, "score": "72.599915"}
{"text": "Other protocol - defined inclusion / exclusion criteria may apply .Gender .Both .Ages .6 Years to 12 Years .Accepts Healthy Volunteers .", "label": "", "metadata": {}, "score": "72.73889"}
{"text": "History of stable body weight , in the judgment of the investigator , for at least 6 months before randomization .No significant change , in the judgment of the investigator , in diet or exercise practices for at least 6 months before randomization and agreement to not change diet or exercise practices during the course of the study .", "label": "", "metadata": {}, "score": "73.7101"}
{"text": "Participants taking prazosin .Prazosin was administered as 1 or 2 mg capsules .Doses were initiated at 1 mg at bedtime .Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4 mg at bedtime .", "label": "", "metadata": {}, "score": "74.288574"}
{"text": "History of sensitivity to any components of the study material or to topical or local anesthetics ( e.g. , lidocaine , benzocaine , or novocaine ) .", "label": "", "metadata": {}, "score": "74.29973"}
{"text": "Change From Double - blind Baseline in Bech Melancholia Subscale Score at Weeks 9 Through 14 [ Time Frame : Weeks 8 ( double - blind baseline ) through 14 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "74.672775"}
{"text": "Originally designed to evaluate Alzheimer 's disease patients in nursing homes , the study now includes outpatients .It is a 9-week placebo - controlled trial . disruptive agitated behaviors ( e.g. , irritability , aggression , uncooperativeness , pacing ) .", "label": "", "metadata": {}, "score": "74.686386"}
{"text": "A history of psychiatric illness or substance use disorder ( e.g. , schizophrenia , bipolar disorder , autism , abuse or dependence , depression , severe Conduct Disorder or severe Oppositional defiant disorder ) .", "label": "", "metadata": {}, "score": "74.8016"}
{"text": "Keywords Carbamazepine Efficacy Mania Therapeutic drug monitoring Valproate December 2008 ( final data collection date for primary outcome measure ) .Current Primary Outcome Measures ICMJE ( submitted : February 22 , 2011 ) .", "label": "", "metadata": {}, "score": "74.99809"}
{"text": "Both the drugs were started with an average dose of approximately 20 mg / kg body weight per day .Further increment in dose was carried out at weekly intervals , guided by clinical improvement , serum levels and treatment emergent adverse events .", "label": "", "metadata": {}, "score": "75.11873"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Efficacy and Safety of Dex - Methylphenidate Extended Release 30 mg Versus 20 mg in Children ( 6 - 12 Years )", "label": "", "metadata": {}, "score": "75.16118"}
{"text": "Significantly more patients in the CBZ group reported adverse events , including nausea , vomiting and dizziness , than VPA .Conclusions : The findings from this study suggest that both CBZ and VPA monotherapy is feasible for treatment of acute mania ; however , VPA is more efficacious in terms of its early onset of action , lesser requirement for rescue medication and better tolerability .", "label": "", "metadata": {}, "score": "75.17942"}
{"text": "The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics ( erythema , thickness , and scaling ) and degree of skin surface area involvement on defined anatomical regions .", "label": "", "metadata": {}, "score": "75.18287"}
{"text": "a. Have moderate to severe plaque psoriasis at Screening and Baseline .Females of childbearing potential ( FCBP ) must have a negative pregnancy test at Screening and Baseline .", "label": "", "metadata": {}, "score": "75.32"}
{"text": "Of the VPA treated patients , 73 % showed a favourable clinical response while 53 % of the patients on CBZ responded favourably .In the CBZ group , significantly more patients received rescue medication during the week 2 and the requirement was quantitatively more as compared to the VPA group .", "label": "", "metadata": {}, "score": "75.42624"}
{"text": "[ Time Frame : at day 21 and month 12 ] [ Designated as safety issue : No ] . -Decrease of CK levels [ Time Frame : at day 21 and month 12 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "75.74101"}
{"text": "Change in Neuropsychiatric Inventory ( NPI ) Total Score Over the Course of Study Participation [ Time Frame : Weeks 2 , 4 , 6 , and 8 ( change from Baseline ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "75.773056"}
{"text": "Refractory to the conventional treatments Resistance to conventional treatments is defined as an inadequate response to , or intolerable side effects with conventional treatments , such as corticosteroids , azathioprine , methotrexate , cyclophosphamide , cyclosporine , IgIV and/or plasma exchange .", "label": "", "metadata": {}, "score": "75.87412"}
{"text": "Refractory to the conventional treatments Resistance to conventional treatments is defined as an inadequate response to , or intolerable side effects with conventional treatments , such as corticosteroids , azathioprine , methotrexate , cyclophosphamide , cyclosporine , IgIV and/or plasma exchange .", "label": "", "metadata": {}, "score": "75.87412"}
{"text": "Subjects should be on a stabilized total daily dose or nearest equivalent of 40 - 60 mg methylphenidate or 20 - 30 mg of d - methylphenidate for at least two weeks prior to Screening visit .", "label": "", "metadata": {}, "score": "75.99292"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01294644 The primary objectives of this study are to : 1 ) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy ( ADT ) in patients with Major Depressive Disorder ( MDD ) using the Montgomery Asberg Depression Rating Scale ( MADRS ) .", "label": "", "metadata": {}, "score": "76.44633"}
{"text": "There were no concerns regarding subject safety .Patients must have a primary current diagnosis of MDD without psychotic features .Patients must be receiving ongoing antidepressant therapy at the time of screening .", "label": "", "metadata": {}, "score": "77.30089"}
{"text": "Specific AAbs : anti - synthetases ( anti - JO1 , anti - PL7 , or anti - PL12 ) , or anti - SRP .", "label": "", "metadata": {}, "score": "77.45476"}
{"text": "History of allergy to any component of the study drug .Hepatitis B surface antigen positive at Screening .Anti - hepatitis C antibody positive at Screening .", "label": "", "metadata": {}, "score": "78.707825"}
{"text": "Drug : Apremilast .Drug : Topical treatments or phototherapy .At week 32 , participants considered partial responders or non - responders had the option of adding topical therapies and/or phototherapy to their treatment regimen .", "label": "", "metadata": {}, "score": "78.83104"}
{"text": "Primary Purpose : Treatment .Official Title : .Phase 3 , Multicenter , Randomized , Double - blind , Placebo - controlled Study of ATX-101 ( Sodium Deoxycholate Injection )", "label": "", "metadata": {}, "score": "78.95451"}
{"text": "Females of childbearing potential must have a negative human chorionic gonadotropin ( hCG ) test result within 28 days before randomization and agree to practice medically acceptable birth control during the course of the study .", "label": "", "metadata": {}, "score": "79.421425"}
{"text": "How attractive do you think your overall appearance ( chin / neck , eyes , nose , mouth , entire face ) is / are ?", "label": "", "metadata": {}, "score": "79.64361"}
{"text": "[ Time Frame : at month 12 ] [ Designated as safety issue : No ] .- Score of muscular strength ( Kendall 's muscular testing for myositis or MG muscular score for myasthenia )", "label": "", "metadata": {}, "score": "79.82906"}
{"text": "However , up to 70 % of treated patients show an incomplete response , including 10 - 30 % who are unresponsive .The therapeutical schema is rituximab 1000 mg , 2 times ( at day 0 and 15 ) , followed by one single injection ( 1000 mg ) 6 months latter and end of follow up at 1 year .", "label": "", "metadata": {}, "score": "80.34622"}
{"text": "Body mass index ( BMI ) greater than 30 .Currently on or considering starting a weight reduction regimen .Any medical condition ( e.g. , respiratory , cardiovascular , hepatic , neurological disease , uncontrolled hypertension , or thyroid dysfunction ) that would interfere with assessment of safety or efficacy or compromise the subject 's ability to undergo study procedures or provide informed consent .", "label": "", "metadata": {}, "score": "80.56526"}
{"text": "An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose .", "label": "", "metadata": {}, "score": "80.75304"}
{"text": "SAMJ , S. Afr . med .j. [ online].2012 , vol.102 , n.6 , pp .541 - 544 .ISSN 2078 - 5135 .", "label": "", "metadata": {}, "score": "81.01847"}
{"text": "SAMJ , S. Afr . med .j. [ online].2012 , vol.102 , n.6 , pp .541 - 544 .ISSN 2078 - 5135 .", "label": "", "metadata": {}, "score": "81.01847"}
{"text": "SAMJ , S. Afr . med .j. [ online].2012 , vol.102 , n.6 , pp .541 - 544 .ISSN 2078 - 5135 .", "label": "", "metadata": {}, "score": "81.01847"}
{"text": "Population Pharmacokinetics [ Time Frame : Weeks 11,12 and 14 ] [ Designated as safety issue : No ] .Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling ( NONMEM ) software .", "label": "", "metadata": {}, "score": "81.77078"}
{"text": "Patients with a clinical diagnosis of acute stroke with onset of stroke symptoms within 4.5 hours of receiving thrombolysis were included .Exclusion criteria were based on the National Institute of Neurological Disorders and Stroke ( NINDS ) rt - PA trial protocol ( upper age limit was 75 years ) .", "label": "", "metadata": {}, "score": "81.89842"}
{"text": "Patients with a clinical diagnosis of acute stroke with onset of stroke symptoms within 4.5 hours of receiving thrombolysis were included .Exclusion criteria were based on the National Institute of Neurological Disorders and Stroke ( NINDS ) rt - PA trial protocol ( upper age limit was 75 years ) .", "label": "", "metadata": {}, "score": "81.89842"}
{"text": "Patients with a clinical diagnosis of acute stroke with onset of stroke symptoms within 4.5 hours of receiving thrombolysis were included .Exclusion criteria were based on the National Institute of Neurological Disorders and Stroke ( NINDS ) rt - PA trial protocol ( upper age limit was 75 years ) .", "label": "", "metadata": {}, "score": "81.89842"}
{"text": "Alefacept , briakinumab , or ustekinumab within 24 weeks prior to randomization .Use of any investigational drug within 4 weeks prior to randomization .Prolonged sun exposure or use of tanning booths or other ultraviolet ( UV ) light sources .", "label": "", "metadata": {}, "score": "81.90973"}
{"text": "Recently , interest has grown in the pivotal role of B cells for auto - immune humorally mediated diseases .Rituximab could then be a potential new biological treatment for such diseases , especially for patients refractory to conventional therapies .", "label": "", "metadata": {}, "score": "82.211975"}
{"text": "Alcohol or substance abuse or dependence .Treatment with a monoamine oxidase inhibitor within 10 weeks of enrollment .Pregnancy or breastfeeding .Clinically significant abnormalities on laboratory tests , electrocardiogram , or physical or neurologic examination .", "label": "", "metadata": {}, "score": "82.37522"}
{"text": "Number of Participants With Adverse Events ( AE ) in the Placebo Controlled Phase [ Time Frame : Week 0 to Week 16 ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "82.553085"}
{"text": "Generalised MG .Generalised seropositive MG as defined by the Texas Clinical Classification System : .Extraocular muscle weakness quantified with MG muscle score ( MMS ) , whose inter and inter observer reproducibility has been demonstrated [ 44].", "label": "", "metadata": {}, "score": "83.85341"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "84.06388"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "84.06388"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "84.06388"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "84.06388"}
{"text": "This study will evaluate the efficacy and safety of Dex - Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6 - 12 with Attention - Deficit Hyperactivity Disorder ( ADHD ) in a 12-hour laboratory classroom setting .", "label": "", "metadata": {}, "score": "84.293945"}
{"text": "Exclusion Criteria : .Other than psoriasis , history of any clinically significant ( as determined by the Investigator ) or other major uncontrolled disease .", "label": "", "metadata": {}, "score": "84.52457"}
{"text": "Official Title : .A Phase 3 , Multicenter , Randomized , Double - Blind , Placebo - Controlled , Efficacy and Safety Study of Apremilast ( CC-10004 ) in Subjects With Moderate to Severe Plaque Psoriasis .", "label": "", "metadata": {}, "score": "84.948204"}
{"text": "Detailed Description : .Although the occurrence of disruptive agitation behaviors likely are influenced by environmental/ interpersonal factors , it is also likely that behaviorally relevant neurobiologic abnormalities lower the threshold for the expression of such behavior in Alzheimer 's disease .", "label": "", "metadata": {}, "score": "85.04396"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "85.60535"}
{"text": "Cardiovascular : unstable angina , recent myocardial infarction , second or third degree atrioventricular ( AV ) block , preexisting hypotension ( systolic blood pressure less than 110 ) or orthostatic hypotension .", "label": "", "metadata": {}, "score": "85.811325"}
{"text": "Drug : Apremilast .Other Names : . CC-10004 .Otezla .Drug : Placebo .Identical matching placebo .Placebo Comparator : Placebo .Subjects initially randomized to placebo , are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject 's participation in the study .", "label": "", "metadata": {}, "score": "85.8697"}
{"text": "BSA was a measurement of involved skin .The overall BSA affected by psoriasis was estimated based on the palm area of the participant 's hand ( entire palmar surface or \" handprint \" including the fingers ) , which equates to approximately 1 % of total body surface area .", "label": "", "metadata": {}, "score": "85.871475"}
{"text": "Clinically significant abnormality on 12-Lead Electrocardiogram ( ECG ) at Screening .Clinically significant abnormal chest x - ray .History of positive human immunodeficiency virus ( HIV ) , or have congenital or acquired immunodeficiency .", "label": "", "metadata": {}, "score": "86.08358"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 4 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Crossover Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "86.238205"}
{"text": "Rationale : Search for alternatives to lithium therapy for mood disorders commenced with anticonvulsants , carbamazepine ( CBZ ) and valproic acid ( VPA ) , in the late 1970s .", "label": "", "metadata": {}, "score": "86.62155"}
{"text": "Exclusion Criteria : .History of any intervention to treat submental fat ( e.g. , liposuction , surgery , or lipolytic agents ) or trauma associated with the chin or neck areas , which in the judgment of the investigator may affect evaluation of safety or efficacy of treatment .", "label": "", "metadata": {}, "score": "87.12409"}
{"text": "Official Title ICMJE .A Randomized , Multi - center , Double - blind , Placebo - controlled , Cross - over Study Evaluating the Safety and Efficacy of Dex - Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP - Combined Scores in Children With Attention - Deficit / Hyperactivity Disorder ( ADHD ) in a Laboratory Classroom Setting .", "label": "", "metadata": {}, "score": "88.462364"}
{"text": "Links relacionados .Compartir .SAMJ : South African Medical Journal .versi\u00f3n On - line ISSN 2078 - 5135 .Resumen .WASSERMAN , Sean y BRYER , Alan .", "label": "", "metadata": {}, "score": "90.230606"}
{"text": "Other Names : . CC-10004 .Otezla .Drug : Placebo .Identical matching placebo .Active Comparator : Apremilast 30 mg .Apremilast 30 mg by mouth ( PO ) twice a day ( BID ) .", "label": "", "metadata": {}, "score": "91.11963"}
{"text": "Systemic therapy for psoriasis within 4 weeks prior to randomization .Use of phototherapy within 4 weeks prior to randomization ( ie , Ultraviolet B ( UVB ) , psoralen and ultraviolet A ( PUVA ) .", "label": "", "metadata": {}, "score": "91.53643"}
{"text": "Bacterial infections requiring treatment with oral or injectable antibiotics , or significant viral or fungal infections , within 4 weeks of Screening .Psoriasis flare or rebound within 4 weeks prior to Screening .", "label": "", "metadata": {}, "score": "91.63226"}
{"text": "Detailed Description : .Rituximab , a chimeric monoclonal antibody specific for human CD20 , which targets B lymphocytes , has been first developed as biotherapy for the treatment of B lymphoma .", "label": "", "metadata": {}, "score": "92.50089"}
{"text": "Prominent platysmal bands at rest or other anatomical features that , in the judgment of the investigator , may interfere with the evaluation of submental fat or result in an aesthetically unacceptable outcome .", "label": "", "metadata": {}, "score": "92.65846"}
{"text": "Subject or subject 's guardian unable to understand or follow instructions necessary to participate in the study .Diagnosed with or history of a tic disorder or Tourette 's syndrome .", "label": "", "metadata": {}, "score": "92.86676"}
{"text": "Related links .Share .SAMJ : South African Medical Journal .On - line version ISSN 2078 - 5135 .Abstract .WASSERMAN , Sean and BRYER , Alan .", "label": "", "metadata": {}, "score": "92.99836"}
{"text": "The presence of a known medical condition that would preclude the use of methylphenidate .A history ( within the past year ) or presence of clinically significant cardiovascular , cerebrovascular , renal , hepatic , gastrointestinal , pulmonary , immunological , hematological , endocrine , or neurological disease .", "label": "", "metadata": {}, "score": "93.48175"}
{"text": "The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer 's disease ( AD ) and other types of dementia in late life .", "label": "", "metadata": {}, "score": "95.010056"}
{"text": "Although the physiopathogenesis of these two conditions differ , both can be associated with specific auto - antibodies ( AAbs ) and their therapeutic management is almost similar .", "label": "", "metadata": {}, "score": "95.21074"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01098240 The traditional treatment of inflammatory myopathies ( IM ) and generalized myasthenia gravis ( MG ) is immunosuppressive therapy , usually beginning with corticosteroids .", "label": "", "metadata": {}, "score": "96.369125"}
{"text": "Recombinant tissue plasminogen activator ( tPA ) thrombolysis is effective in treating acute ischaemic stroke , but may not be a viable option in developing countries .", "label": "", "metadata": {}, "score": "96.39866"}
{"text": "Recombinant tissue plasminogen activator ( tPA ) thrombolysis is effective in treating acute ischaemic stroke , but may not be a viable option in developing countries .", "label": "", "metadata": {}, "score": "96.39866"}
{"text": "Recombinant tissue plasminogen activator ( tPA ) thrombolysis is effective in treating acute ischaemic stroke , but may not be a viable option in developing countries .", "label": "", "metadata": {}, "score": "96.39866"}
{"text": "Exclusionary medications : current treatment with prazosin , other alpha-1-blockers .Current enrollment in a separate investigational drug trial .Psychoactive medications : subjects may be psychoactive medication - free or be partial responders ( by subjective assessment of referring health care professional ) to one psychoactive medication from any of the following classes : antipsychotics , anticonvulsants , mood stabilizers , antidepressants , benzodiazepines , or buspirone .", "label": "", "metadata": {}, "score": "97.14281"}
{"text": "Drug : Placebo .Placebo Comparator .Study Arm ( s ) .Experimental : Dex - Methylphenidate hydrochloride ( Focalin \u00ae XR ) 30 mg .", "label": "", "metadata": {}, "score": "97.245255"}
{"text": "Note categories below .[ 1 ] Psoriasis adverse events ( ie , preferred term as Guttate psoriasis , Psoriasis , Pustular psoriasis ) started on or after the first dose date and on or before the last dose date within the phase .", "label": "", "metadata": {}, "score": "98.411255"}
{"text": "Intervention : Drug : Dex - Methylphenidate hydrochloride Extended Release ( Focalin \u00ae XR ) .December 2008 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "99.24053"}
{"text": "Links relacionados .Compartilhar .SAMJ : South African Medical Journal .vers\u00e3o On - line ISSN 2078 - 5135 .Resumo .WASSERMAN , Sean e BRYER , Alan .", "label": "", "metadata": {}, "score": "101.743004"}
{"text": "Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention , or a diagnosis of new generalized erythrodermic , inflammatory , or pustular psoriasis .", "label": "", "metadata": {}, "score": "102.25418"}
{"text": "Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects This study evaluated the effects of an called apremilast .Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis .", "label": "", "metadata": {}, "score": "103.12541"}
{"text": "The Pruritus Visual Analog Scores ( VAS ) were used to measure the amount of itching and discomfort a participant experiences .Participant 's Assessment of Pruritus ( Itch ) asked : On average , how much itch have you had because of your condition in the past week ?", "label": "", "metadata": {}, "score": "103.61194"}
{"text": "Intervention : Drug : Dex - Methylphenidate hydrochloride Extended Release ( Focalin \u00ae XR ) .Active Comparator : Dex - Methylphenidate hydrochloride ( Focalin \u00ae XR ) 20 mg .", "label": "", "metadata": {}, "score": "107.85179"}
{"text": "Attention - Deficit / Hyperactivity Disorder ( ADHD ) .Intervention ICMJE .Drug : Dex - Methylphenidate hydrochloride Extended Release ( Focalin \u00ae XR ) .", "label": "", "metadata": {}, "score": "109.91062"}
{"text": "Other Name : Minipress .Placebo Comparator : placebo ( inert substance ) .Drug : placebo ( inert substance ) .Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials .", "label": "", "metadata": {}, "score": "111.44264"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01194219 .Psoriasis Skin Diseases Skin Diseases , Papulosquamous Apremilast Analgesics Analgesics , Non - Narcotic Anti - Inflammatory Agents Anti - Inflammatory Agents , Non - Steroidal Antirheumatic Agents .", "label": "", "metadata": {}, "score": "113.025986"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00161473 .Alzheimer Disease Psychomotor Agitation Brain Diseases Central Nervous System Diseases Delirium , Dementia , Amnestic , Cognitive Disorders Dementia Dyskinesias Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurodegenerative Diseases Neurologic Manifestations Psychomotor Disorders Signs and Symptoms .", "label": "", "metadata": {}, "score": "117.33577"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00774462 .Myositis Muscular Diseases Myasthenia Gravis Autoimmune Diseases Autoimmune Diseases of the Nervous System Immune System Diseases Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases .", "label": "", "metadata": {}, "score": "123.41794"}
